Scarica l'app Stockscreener
3.27
2.39%
-0.08
Dopo l'orario di chiusura:
3.23
-0.04
-1.22%
Polypid Ltd Borsa (PYPD) Ultime notizie
What indicators show strength in PolyPid Ltd.Market Growth Report & High Conviction Investment Ideas - newser.com
How to build a custom watchlist for PolyPid Ltd.2025 Biggest Moves & Weekly Watchlist for Hot Stocks - newser.com
How to use a screener to detect PolyPid Ltd. breakoutsMarket Sentiment Summary & Precise Swing Trade Alerts - newser.com
An Overlooked Crisis in Hospitals Could Be Pharma's Next Great Opportunity - MarketScreener
Weiss Ratings Reaffirms Sell (E+) Rating for PolyPid (NASDAQ:PYPD) - MarketBeat
Analyzing recovery setups for PolyPid Ltd. investors2025 Analyst Calls & Consistent Profit Trade Alerts - newser.com
Is this a good reentry point in PolyPid Ltd.2025 Stock Rankings & Daily Entry Point Trade Alerts - newser.com
Best data tools to analyze PolyPid Ltd. stockMarket Growth Report & Free Long-Term Investment Growth Plans - newser.com
PolyPid Ltd. (NASDAQ:PYPD) Sees Large Increase in Short Interest - Defense World
PolyPid Ltd. (NASDAQ:PYPD) Short Interest Update - MarketBeat
Price action breakdown for PolyPid Ltd.July 2025 Spike Watch & Long-Term Investment Growth Plans - newser.com
Will PolyPid Ltd. see short term momentumBuy Signal & Stock Portfolio Risk Management - newser.com
Tools to monitor PolyPid Ltd. recovery probabilityBreakout Watch & Safe Capital Investment Plans - newser.com
Is PolyPid Ltd a good long term investmentMid Cap Growth Trends & Achieve Consistent Profits - earlytimes.in
PolyPid to present phase 3 SHIELD II trial results at ACS congress - Investing.com Nigeria
PolyPid at Lytham Partners: Strategic Insights on D-PLEX100 By Investing.com - Investing.com Australia
PolyPid at Lytham Partners: Strategic Insights on D-PLEX100 - Investing.com India
PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress - The Manila Times
PolyPid Ltd. Announces Presentation of Phase 3 SHIELD II Trial Results at 2025 ACS Clinical Congress - Quiver Quantitative
PolyPid to Present Its Positive Phase 3 SHIELD II Topline - GlobeNewswire
Key Phase 3 Trial Results: PolyPid's D-PLEX₁₀₀ for Surgical Infection Prevention at Major Surgery Congress - Stock Titan
PolyPid (NASDAQ:PYPD) & Cronos Group (NASDAQ:CRON) Head to Head Survey - Defense World
What analysts say about PolyPid Ltd stockVolume Analysis Techniques & Invest Smarter With Data-Driven Models - earlytimes.in
What drives PolyPid Ltd stock priceFibonacci Retracement Levels & Free Rapid Growing Investment Returns - earlytimes.in
PolyPid Ltd. (NASDAQ:PYPD) Receives $12.40 Consensus PT from Analysts - Defense World
PolyPid (NASDAQ:PYPD) Rating Increased to Hold at Wall Street Zen - MarketBeat
What to expect from PolyPid Ltd. in the next 30 days2025 Major Catalysts & Verified High Yield Trade Plans - newser.com
PolyPid Ltd. (NASDAQ:PYPD) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
PolyPid (NASDAQ:PYPD) Stock Price Up 2.9%Time to Buy? - MarketBeat
PolyPid (NASDAQ:PYPD) Stock Price Up 2.9% – Time to Buy? - Defense World
Will a bounce in PolyPid Ltd. offer an exitBuy Signal & Free Daily Entry Point Trade Alerts - newser.com
Multi factor analysis applied to PolyPid Ltd.Exit Point & Verified High Yield Trade Plans - newser.com
Real time breakdown of PolyPid Ltd. stock performanceMarket Rally & AI Driven Price Predictions - newser.com
Does PolyPid Ltd. show high probability of reboundExit Point & Safe Entry Trade Signal Reports - newser.com
Strategies to average down on PolyPid Ltd.July 2025 Decliners & Weekly High Potential Stock Alerts - newser.com
PolyPid completes Israeli Ministry of Health GMP inspection - MSN
1.84%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):